Is chemotherapy beneficial for elderly patients with advanced non-small-cell lung cancer : analysis of patients aged 70-74 , 75-79 , and 80 or older in Japan?
After adjustment for PS, a trend of survival benefit of chemotherapy remained in patients aged 80 or older.
Basal anti-CCP antibodies levels correlate with clinical response to adalimumab. A decrease in anti-CCP levels on time was observed in patients showing also clinical improvement, suggesting that serum anti-CCP antibodies determination may be useful in assessing treatment efficacy in RA patients.